Australia's most trusted
source of pharma news
Friday, 06 February 2026
Posted 6 February 2026 AM
The obesity giants released their end of year financial reports this week to vastly different effect.
Novo Nordisk saw its share price plummet 17.9 per cent on the release of its full year financials, and it closed 18.6 per cent lower than its previous day's high. That wiped around $50 billion from its market cap.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.